Cyclical etidronate in the treatment of postmenopausal osteoporosis: Efficacy and safety after seven years of treatment

American Journal of Medicine

Volumn 103, Issue 6, 1997, Pages 468-476

  Miller, Paul D ^a   Watts, Nelson B ^b   Licata, Angelo A ^c   Harris, Steven T ^d   Genant, Harry K ^d   Wasnich, Richard D ^e   Ross, Philip D ^e   Jackson, Rebecca D ^f   Hoseyni, Mohammed S ^g   Schoenfeld, Steven L ^h   Valent, David J ^g   Chesnut III, Charles H ⁱ  

^a UNIVERSITY OF COLORADO   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Hawaii Osteoporosis Center   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^h AMYLIN PHARMACEUTICALS INC   (United States)

ⁱ UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CARBONATE; ETIDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DENSITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOLLOW UP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSTEOLYSIS; PATHOLOGIC FRACTURE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; VERTEBRA FRACTURE;

NON-PROGRAMMATIC;

AGED; BONE DENSITY; DRUG ADMINISTRATION SCHEDULE; ETIDRONIC ACID; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 0031460260     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)00278-7     Document Type: Article

References (34)

1. Frost HM. Treatment of osteoporoses by manipulation of coherent bone cell populations. Clin Orthop Related Res. 143:1979;227-244.
2. Meunier PJ, Confavreux E, Tuninon I, Hardouin C. Cyclical etidronate therapy prevents bone loss in the early postmenopausal period. J Bone Miner Res. 1995;10(suppl 1):S357. (Abstract).
3. Herd RJM, Blake GM, Ryan PJ, et al. A 152 patient double blind placebo controlled study of cyclical etidronate therapy for the prevention of early postmenopausal bone loss. J Bone Miner Res. 1995;10(suppl 1):S153. (Abstract).
4. Adachi JD, Cranney A, Goldsmith CH, et al. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss. J Rheumatol. 21:1994;1922-1926.
5. Mulder H, Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol. 33:1994;348-350.
6. Reid IR, Schooler BA, Stewart AW. Prevention of glucocorticoid-induced osteoporosis. J Bone Miner Res. 5:1990;619-623.
7. Diamond T, McGuigan L, Barbagallo S, Bryant C. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women. Am J Med. 98:1995;459-463.
8. Struys A, Snelder AA, Mulder H. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med. 99:1994;235-242.
9. Berenson J, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. NEJM. 334:1996;488-493.
10. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. NEJM. 323:1990;73-79.
11. Harris ST, Watts NB, Jackson RD, et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med. 95:1993;557-567.
12. Storm T, Thamsborg G, Steiniche T, Genant HK, Sørensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. NEJM. 322:1990;1265-1271.
13. Silberstein EB, Schnur W. Cyclic oral phosphate and etidronate increase femoral and lumbar bone mineral density and reduce lumbar spine fracture rate over three years. J Nucl Med. 33:1992;1-5.
14. Licata AA, Chesnut CH III, Genant HK, et al. Effects of 2 years' follow-up cyclical etidronate treatment in postmenopausal osteoporotic women. J Bone Miner Res. 1993;8(suppl 1):S141. (Abstract).
15. Miller PD, Jackson RD, Ross PD, et al. ICT etidronate for osteoporosis: 5-year results. Bone Miner. 1994;25(suppl 1):S74. (Abstract).
16. Genant HK, Wu CY, Van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 8:1993;1137-1148.
17. Storm T, Sorensen HA, Thamsborg G, et al. Bone histomorphometric changes after up to seven years of cyclical etidronate treatment. J Bone Miner Res. 11:(suppl 1):1996;S151.
18. Sahni M, Guenther HL, Fleisch H, et al. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest. 911:1993;2004-2011.
19. Girasole G, Giuliani N, Ulietti V, et al. The bisphosphonates etidronate and alendronate stimulate the formation of osteoblast precursors and mineralized nodules in murine bone marrow cultures. J Bone Miner Res. 1994;9(suppl 1):S343. (Abstract).
20. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing fractures. Lancet. 348:1996;1535-1541.
21. van Staa TP, Abenhaim L, Cooper C. Bone safety of cyclical etidronate. J Bone Miner Res. 1996;11(suppl 1):S343. (Abstract).
22. Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. NEJM. 333:1995;1437-1443.
23. Van Beek E, Hoekstra M, Van De Ruit M, et al. Structural requirements for bisphosphonate actions in vitro. J Bone Miner Res. 9:1994;1875-1882.
24. Christiansen C, Christiansen MS, Transbol I. Bone mass in postmenopausal women after withdrawal of oestrogen/progesterone replacement therapy. Lancet. 1:1981;459-461.
25. Christiansen C. Use of nasally administered salmon calcitonin in preventing bone loss. Calcif Tissue Int. 49:1991;S14-S15.
26. Storm T, Steiniche T, Thamsborg G, Melsen F. Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis. J Bone Miner Res. 8:1993;199-208.
27. Heaney RP, Saville PD. Etidronate disodium in postmenopausal osteoporosis. Clin Pharmacol Ther. 20:1976;593-604.
28. Krane SM. Etidronate disodium in the treatment of Paget's disease of bone. Ann Intern Med. 96:1982;619-625.
29. Ott SM, Woodson GC, Huffer WE, et al. Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis. J Clin Endocrinol Metab. 78:1994;968-972.
30. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. J Bone Miner Res. 2:1987;595-610.
31. Lufkin EG, Argueta R, Whitaker MD, et al. Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporosis Int. 4:1994;320-322.
32. Maconi G, Porro GB. Multiple ulcerative esophagitis caused by alendronate. Am J Gastroenterol. 90:1995;1889.
33. de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. NEJM. 335:1996;1016-1021.
34. van Staa TP, Abenhaim L, Cooper C. Upper gastrointestinal safety profile of cyclical etidronate. J Bone Miner Res. 1996;11(suppl 1):S343. (Abstract).